Inserm, BPH Research Center, Team Pharmacoepidemiology, UMR 1219, Univ. Bordeaux, Bordeaux, France.
Pôle de Santé Publique, Service de Pharmacologie médicale, CHU Bordeaux, Bordeaux, France.
Fundam Clin Pharmacol. 2022 Apr;36(2):421-426. doi: 10.1111/fcp.12735. Epub 2021 Nov 16.
Owing to a broad spectrum and low cost antimicrobial, cotrimoxazole is largely prescribed. However, its use is associated with various adverse drug reactions (ADRs) that warrant to ensure rational prescribing. This study aimed to describe spontaneous reports of cotrimoxazole ADRs and to evaluate the quality of prescription in patients who had ADRs. Suspected cotrimoxazole-induced ADRs cases reported to the Bordeaux regional pharmacovigilance center (France) during a 5-year period were described. Seriousness was assessed according to international criteria. Quality of prescription was assessed by compliance with the Summary of Product Characteristics (SPC) and relevance of cotrimoxazole indication. Then, an ADR was considered as preventable if the cotrimoxazole indication was not relevant, or potentially preventable if indication was relevant but the prescription was not compliant with the SPC. A total of 96 cases were analyzed: median age was 60.5 years (range: 4-94); 59.4% of patients were male. ADRs were mostly cutaneous disorders (n = 46) and hematological disorders (n = 25). A total of 60 serious ADRs occurred in 55 patients. Prescribers complied with all SPC recommendations in 21.9% of cases. Indication of cotrimoxazole was relevant or highly relevant in 41 cases. In 58% of cases, the occurrence of a cotrimoxazole-induced ADR would have been preventable or potentially preventable. In a context of increasing interest for this antibiotic to treat infections due to resistant bacteria, physicians should be more aware of the potential consequences of inappropriate prescribing cotrimoxazole and reserve its use when there is no alternative and under suitable monitoring.
由于复方新诺明具有广谱和低成本的抗菌作用,因此被广泛应用。然而,其使用与各种不良反应(ADR)有关,这需要确保合理用药。本研究旨在描述复方新诺明 ADR 的自发报告,并评估发生 ADR 的患者的处方质量。描述了在 5 年内向波尔多地区药物警戒中心(法国)报告的疑似复方新诺明引起的 ADR 病例。根据国际标准评估严重程度。通过遵守产品特性摘要(SPC)和复方新诺明适应症的相关性来评估处方质量。如果复方新诺明的适应症不相关,则认为 ADR 可预防,如果适应症相关但处方不符合 SPC,则认为 ADR 可能可预防。共分析了 96 例病例:中位年龄为 60.5 岁(范围:4-94);59.4%的患者为男性。ADR 主要为皮肤疾病(n=46)和血液疾病(n=25)。共有 55 名患者发生 60 例严重 ADR。在 21.9%的情况下,处方者遵守了所有 SPC 建议。在 41 例中,复方新诺明的适应症是相关或高度相关的。在 58%的情况下,使用复方新诺明引起的 ADR 是可以预防或可能预防的。在对抗生素耐药菌引起的感染治疗中,复方新诺明的应用日益受到关注,医生应更加意识到不当使用复方新诺明的潜在后果,并在没有替代药物且适合监测的情况下保留其使用。